GST rates slashed for certain cancer drugs Yakshi Chugh10 Sept 2024 5:20 PM ISTNew Delhi: In an effort to reduce the overall cost for the treatment of cancer, the GST Council decided to reduce the GST rate on certain cancer drugs...
Health Bulletin 10/ September/ 2024 Yakshi Chugh10 Sept 2024 5:17 PM ISTHere are the Top health stories for the day: MCC NEET PG counselling 2024 tentative schedule out, registrations from Sept 20New Delhi- The...
GST rates reduced from 12 percent to 5 per cent on certain cancer drugs Ruchika Sharma10 Sept 2024 2:36 PM ISTNew Delhi: In an effort to reduce the overall cost for the treatment of cancer, the GST Council decided to reduce the GST rate on certain cancer...
Imfinzi, Lynparza combo approved in EU for mismatch repair proficient advanced or recurrent endometrial cancer: AstraZeneca Ruchika Sharma18 Aug 2024 10:00 AM ISTCambridge: AstraZeneca's Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain...
AstraZeneca Imfinzi in combo with chemotherapy gets USFDA approval for treatment of resectable non-small cell lung cancer before and after surgery Ruchika Sharma17 Aug 2024 1:30 PM ISTCambridge: AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult...
AstraZeneca Imfinzi gets USFDA priority review for limited-stage small cell lung cancer Ruchika Sharma16 Aug 2024 12:30 PM ISTCambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), based on the results from the positive...
FDA Advisory Committee reviewed Imfinzi for resectable non-small cell lung cancer based on AEGEAN Phase III trial results Ruchika Sharma28 July 2024 4:15 PM ISTThe Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has acknowledged that AstraZeneca's Imfinzi (durvalumab) met...
Health Bulletin 24/ July/ 2024 Anshika Mishra24 July 2024 4:26 PM ISTHere are the top health news for the day:Chandipura virus: More than 32 dead in worst outbreak in over 20 yearsThe worst outbreak of the Chandipura...
Lynparza, Imfinzi combo recommended for nod in EU by CHMP for endometrial cancer: AstraZeneca Ruchika Sharma3 July 2024 10:00 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU)...
AstraZeneca Imfinzi fails in late-stage trial to treat type of lung cancer Ruchika Sharma30 Jun 2024 11:30 AM ISTCambridge: AstraZeneca has announced the high-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials...
AstraZeneca Imfinzi plus chemotherapy gets USFDA nod for mismatch repair deficient advanced or recurrent endometrial cancer Ruchika Sharma17 Jun 2024 11:30 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has...
Submit analysis of clinical data of Asian, Indian Population: CDSCO Panel Tells AstraZeneca on Durvalumab Dr. Divya Colin13 April 2024 6:00 PM ISTNew Delhi: In response to the drug major AstraZeneca's proposal for the approval of additional indication of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL...
